Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer

Abstract While adjuvant treatment with the selective-estrogen receptor modulator (SERM) tamoxifen has been the standard of care for pre-menopausal patients with hormone receptor (HR) positive breast cancer, recent trials showed a benefit of aromatase inhibitors (AI) and ovarian function suppression...

Full description

Bibliographic Details
Main Authors: Helena Record, Elle Clelland, Harriet T. Rothschild, Mandeep Kaur, A. Jo Chien, Michelle Melisko, Hope S. Rugo, Firdows Mujir, Laura Huppert, Rita A. Mukhtar
Format: Article
Language:English
Published: Nature Portfolio 2023-10-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00594-3

Internet

https://doi.org/10.1038/s41523-023-00594-3

Similar Items